• Something wrong with this record ?

Improving the Clinical Application of Natural Killer Cells by Modulating Signals Signal from Target Cells

M. Holubova, M. Leba, H. Gmucova, VS. Caputo, P. Jindra, D. Lysak,

. 2019 ; 20 (14) : . [pub] 20190715

Language English Country Switzerland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19044661

Grant support
15-30661A Ministerstvo Zdravotnictví Ceské Republiky

Relapsed acute myeloid leukemia (AML) is a significant post-transplant complication lacking standard treatment and associated with a poor prognosis. Cellular therapy, which is already widely used as a treatment for several hematological malignancies, could be a potential treatment alternative. Natural killer (NK) cells play an important role in relapse control but can be inhibited by the leukemia cells highly positive for HLA class I. In order to restore NK cell activity after their ex vivo activation, NK cells can be combined with conditioning target cells. In this study, we tested NK cell activity against KG1a (AML cell line) with and without two types of pretreatment-Ara-C treatment that induced NKG2D ligands (increased activating signal) and/or blocking of HLA-KIR (killer-immunoglobulin-like receptors) interaction (decreased inhibitory signal). Both treatments improved NK cell killing activity. Compared with target cell killing of NK cells alone (38%), co-culture with Ara-C treated KG1a target cells increased the killing to 80%. Anti-HLA blocking antibody treatment increased the proportion of dead KG1a cells to 53%. Interestingly, the use of the combination treatment improved the killing potential to led to the death of 85% of KG1a cells. The combination of Ara-C and ex vivo activation of NK cells has the potential to be a feasible approach to treat relapsed AML after hematopoietic stem cell transplantation.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044661
003      
CZ-PrNML
005      
20200604145547.0
007      
ta
008      
200109s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms20143472 $2 doi
035    __
$a (PubMed)31311121
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Holubova, Monika $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen 323 00, Czech Republic. holubovam@fnplzen.cz.
245    10
$a Improving the Clinical Application of Natural Killer Cells by Modulating Signals Signal from Target Cells / $c M. Holubova, M. Leba, H. Gmucova, VS. Caputo, P. Jindra, D. Lysak,
520    9_
$a Relapsed acute myeloid leukemia (AML) is a significant post-transplant complication lacking standard treatment and associated with a poor prognosis. Cellular therapy, which is already widely used as a treatment for several hematological malignancies, could be a potential treatment alternative. Natural killer (NK) cells play an important role in relapse control but can be inhibited by the leukemia cells highly positive for HLA class I. In order to restore NK cell activity after their ex vivo activation, NK cells can be combined with conditioning target cells. In this study, we tested NK cell activity against KG1a (AML cell line) with and without two types of pretreatment-Ara-C treatment that induced NKG2D ligands (increased activating signal) and/or blocking of HLA-KIR (killer-immunoglobulin-like receptors) interaction (decreased inhibitory signal). Both treatments improved NK cell killing activity. Compared with target cell killing of NK cells alone (38%), co-culture with Ara-C treated KG1a target cells increased the killing to 80%. Anti-HLA blocking antibody treatment increased the proportion of dead KG1a cells to 53%. Interestingly, the use of the combination treatment improved the killing potential to led to the death of 85% of KG1a cells. The combination of Ara-C and ex vivo activation of NK cells has the potential to be a feasible approach to treat relapsed AML after hematopoietic stem cell transplantation.
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a kultivované buňky $7 D002478
650    _2
$a klinické zkoušky jako téma $7 D002986
650    _2
$a cytarabin $x farmakologie $7 D003561
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x farmakologie $7 D007166
650    _2
$a imunoterapie $x metody $7 D007167
650    _2
$a buňky NK $x účinky léků $x imunologie $x transplantace $7 D007694
650    _2
$a akutní myeloidní leukemie $x imunologie $x terapie $7 D015470
650    _2
$a lektinové receptory NK-buněk - podrodina K $x imunologie $7 D055655
650    _2
$a receptory KIR $x imunologie $7 D054340
650    _2
$a signální transdukce $7 D015398
655    _2
$a časopisecké články $7 D016428
700    1_
$a Leba, Martin $7 xx0248641 $u Faculty of Applied Science, University of West Bohemia, Pilsen 301 00, Czech Republic.
700    1_
$a Gmucova, Hana $u Department of Haematology and Oncology, University Hospital Pilsen, Pilsen 304 60, Czech Republic.
700    1_
$a Caputo, Valentina S $u Centre for Haematology, Department of Medicine, Imperial College London, London, W12 0NN, UK.
700    1_
$a Jindra, Pavel $u Department of Haematology and Oncology, University Hospital Pilsen, Pilsen 304 60, Czech Republic.
700    1_
$a Lysak, Daniel $u Department of Haematology and Oncology, University Hospital Pilsen, Pilsen 304 60, Czech Republic.
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 20, č. 14 (2019)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31311121 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200604145545 $b ABA008
999    __
$a ok $b bmc $g 1482930 $s 1083334
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 20 $c 14 $e 20190715 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a 15-30661A $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Archiving options